(GILD) Gilead Sciences - Overview
Stock: Antivirals, Oncology, HIV, Hepatitis, COVID-19
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.79% |
| Yield on Cost 5y | 5.59% |
| Yield CAGR 5y | 2.71% |
| Payout Consistency | 100.0% |
| Payout Ratio | 50.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Relative Tail Risk | -5.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 43.01 |
| Character TTM | |
|---|---|
| Beta | 0.374 |
| Beta Downside | 0.309 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| CAGR/Max DD | 0.87 |
Description: GILD Gilead Sciences January 27, 2026
Gilead Sciences (NASDAQ:GILD) is a global biopharmaceutical firm that discovers, develops, and markets medicines for high-unmet-need areas, including HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension, and serious fungal infections. Its product suite spans blockbuster HIV regimens (e.g., Biktarvy, Descovy), the antiviral Veklury for COVID-19, hepatitis cures (Epclusa, Harvoni), and newer oncology assets such as Yescarta, Tecartus, and Trodelvy. The company also maintains a broad network of collaborations with firms like Merck, Galapagos, and Arcus to expand its pipeline across immuno-oncology and small-molecule therapeutics.
Key recent metrics (Q4 2025 results, released Feb 2026) show total revenue of **$6.4 billion**, with the HIV portfolio still contributing roughly **30 %** of sales despite a 4 % YoY decline. Net income rose to **$4.2 billion**, driven by cost-containment and higher margins on COVID-19 and hepatitis products. R&D expenditure reached **$4.3 billion**, reflecting accelerated investment in the Trodelvy expansion and dual-target trispecific antibody programs. The biotech sector is currently benefitting from a **12 % YTD gain in the MSCI US Biotechnology Index**, while pricing pressures from CMS and a tighter FDA review environment remain material risk factors.
For a deeper quantitative assessment, consider reviewing ValueRay’s analyst dashboards for GILD.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 8.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.64 > 1.0 |
| NWC/Revenue: 19.17% < 20% (prev 10.80%; Δ 8.38% < -1%) |
| CFO/TA 0.17 > 3% & CFO 9.67b > Net Income 8.11b |
| Net Debt (17.61b) to EBITDA (13.67b): 1.29 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.25b) vs 12m ago 0.0% < -2% |
| Gross Margin: 78.71% > 18% (prev 0.76%; Δ 7795 % > 0.5%) |
| Asset Turnover: 51.45% > 50% (prev 51.90%; Δ -0.45% > 0%) |
| Interest Coverage Ratio: 10.70 > 6 (EBITDA TTM 13.67b / Interest Expense TTM 1.02b) |
Altman Z'' 3.00
| A: 0.10 (Total Current Assets 17.87b - Total Current Liabilities 12.30b) / Total Assets 58.53b |
| B: 0.22 (Retained Earnings 12.82b / Total Assets 58.53b) |
| C: 0.19 (EBIT TTM 10.90b / Avg Total Assets 56.53b) |
| D: 0.35 (Book Value of Equity 12.86b / Total Liabilities 37.08b) |
| Altman-Z'' Score: 3.00 = A |
Beneish M -3.02
| DSRI: 1.08 (Receivables 5.09b/4.59b, Revenue 29.09b/28.30b) |
| GMI: 0.97 (GM 78.71% / 76.11%) |
| AQI: 0.95 (AQ_t 0.60 / AQ_t-1 0.63) |
| SGI: 1.03 (Revenue 29.09b / 28.30b) |
| TATA: -0.03 (NI 8.11b - CFO 9.67b) / TA 58.53b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of GILD shares?
Over the past week, the price has changed by +1.64%, over one month by +21.12%, over three months by +18.17% and over the past year by +49.71%.
Is GILD a buy, sell or hold?
- StrongBuy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GILD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 139.5 | -2.7% |
| Analysts Target Price | 139.5 | -2.7% |
| ValueRay Target Price | 181.8 | 26.9% |
GILD Fundamental Data Overview February 03, 2026
P/E Forward = 15.873
P/S = 6.0554
P/B = 8.0379
P/EG = 0.2542
Revenue TTM = 29.09b USD
EBIT TTM = 10.90b USD
EBITDA TTM = 13.67b USD
Long Term Debt = 22.14b USD (from longTermDebt, last quarter)
Short Term Debt = 2.81b USD (from shortTermDebt, last quarter)
Debt = 24.94b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.61b USD (from netDebt column, last quarter)
Enterprise Value = 193.72b USD (176.13b + Debt 24.94b - CCE 7.35b)
Interest Coverage Ratio = 10.70 (Ebit TTM 10.90b / Interest Expense TTM 1.02b)
EV/FCF = 21.14x (Enterprise Value 193.72b / FCF TTM 9.16b)
FCF Yield = 4.73% (FCF TTM 9.16b / Enterprise Value 193.72b)
FCF Margin = 31.50% (FCF TTM 9.16b / Revenue TTM 29.09b)
Net Margin = 27.88% (Net Income TTM 8.11b / Revenue TTM 29.09b)
Gross Margin = 78.71% ((Revenue TTM 29.09b - Cost of Revenue TTM 6.19b) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 78.80%)
Tobins Q-Ratio = 3.31 (Enterprise Value 193.72b / Total Assets 58.53b)
Interest Expense / Debt = 1.03% (Interest Expense 256.0m / Debt 24.94b)
Taxrate = 16.18% (589.0m / 3.64b)
NOPAT = 9.14b (EBIT 10.90b * (1 - 16.18%))
Current Ratio = 1.45 (Total Current Assets 17.87b / Total Current Liabilities 12.30b)
Debt / Equity = 1.16 (Debt 24.94b / totalStockholderEquity, last quarter 21.54b)
Debt / EBITDA = 1.29 (Net Debt 17.61b / EBITDA 13.67b)
Debt / FCF = 1.92 (Net Debt 17.61b / FCF TTM 9.16b)
Total Stockholder Equity = 19.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.35% (Net Income 8.11b / Total Assets 58.53b)
RoE = 40.70% (Net Income TTM 8.11b / Total Stockholder Equity 19.93b)
RoCE = 25.93% (EBIT 10.90b / Capital Employed (Equity 19.93b + L.T.Debt 22.14b))
RoIC = 20.17% (NOPAT 9.14b / Invested Capital 45.31b)
WACC = 6.49% (E(176.13b)/V(201.07b) * Re(7.29%) + D(24.94b)/V(201.07b) * Rd(1.03%) * (1-Tc(0.16)))
Discount Rate = 7.29% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.08%
[DCF Debug] Terminal Value 83.41% ; FCFF base≈9.27b ; Y1≈8.88b ; Y5≈8.64b
Fair Price DCF = 160.5 (EV 216.68b - Net Debt 17.61b = Equity 199.07b / Shares 1.24b; r=6.49% [WACC]; 5y FCF grow -5.51% → 2.90% )
EPS Correlation: -16.02 | EPS CAGR: -20.89% | SUE: -4.0 | # QB: 0
Revenue Correlation: 43.72 | Revenue CAGR: 1.88% | SUE: 1.15 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.98 | Chg30d=-0.043 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=8.74 | Chg30d=-0.004 | Revisions Net=+5 | Growth EPS=+7.7% | Growth Revenue=+3.3%